Established in 2017 by two innovators in genome editing technology, Qihan Biotech possesses leading-edge capabilities in multiplexable genome editing and extensive expertise in immune protection. These tools are utilized in the development of immune-privileged cell and organ therapies in both human stem cells and animal germline cells, aiming to make cell and organ therapies universally accessible to patients. By employing multiplexable genome editing and in-depth knowledge in transplantation immunology, we aim to create immunologically privileged allogeneic cells and xenogeneic organs as therapies for cancer treatment and beyond.
Qihan Biotech
Headquarters
People's Republic of China